Compare · DHR vs MDT
DHR vs MDT
Side-by-side comparison of Danaher Corporation (DHR) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- DHR operates in Industrials, while MDT operates in Health Care - the two are in different parts of the market.
- DHR is the larger of the two at $163.93B, about 1.2x MDT ($131.57B).
- DHR has been more active in the news (18 items in the past 4 weeks vs 16 for MDT).
- Both have 25 recent analyst ratings on file.
- Company
- Danaher Corporation
- Medtronic plc.
- Price
- -
- -
- Market cap
- $163.93B
- $131.57B
- 1M return
- +0.67%
- -
- 1Y return
- +5.33%
- -
- Industry
- Industrial Machinery/Components
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 18
- 16
- Recent ratings
- 25
- 25
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest DHR
- Executive Vice President Milosevich Gregory M sold $484,302 worth of shares (2,100 units at $230.62), decreasing direct ownership by 9% to 22,367 units (SEC Form 4)
- Executive Vice President Mcgrew Matthew exercised 17,385 shares at a strike of $88.24 and sold $4,097,452 worth of shares (17,385 units at $235.69) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Danaher Corporation
- Why the Next Edge in Antibody Discovery May Be What Labs Remember
- Integrated DNA Technologies and Aldevron Launch New mRNA Solutions to Simplify Base and Prime Editing
- Director Dewan Feroz was granted 144 phantom shares (SEC Form 4)
- Director Zerhouni Elias A. was granted 199 phantom shares (SEC Form 4)
- Director Filler Linda was granted 15 phantom shares (SEC Form 4)
- Director Stevens Raymond C was granted 153 phantom shares (SEC Form 4)
- Director List Teri was granted 13 phantom shares (SEC Form 4)
Latest MDT
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
- SEC Form SCHEDULE 13G filed by Medtronic plc.
- Imperative Care Announces Two New Board of Directors Appointments
- Orchestra BioMed Announces Pricing of Public Offering
- Orchestra BioMed Announces Proposed Public Offering
- President Marinaro Michael was granted 6,547 units of Ordinary Shares, increasing direct ownership by 6% to 113,353 units (SEC Form 4)
- Medtronic to announce financial results for its second quarter of fiscal year 2027
- /C O R R E C T I O N - The Michael J. Fox Foundation for Parkinson's Research/
- Michael J. Fox Foundation and Medtronic Partner to Help More People with Parkinson's Understand Deep Brain Stimulation
- Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation